Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 9/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 7/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582871 | 0.90 | PRKAA2 (0.60) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4581027 | 0.85 | CCNC (0.44) | — | |
| SCHEMBL4581650 | 0.84 | DRD4 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4580445 | 0.83 | PRKAA2 (0.52) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4581243 | 0.80 | PRKAA2 (0.52) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL15741796 | 0.79 | HPGD (0.44) | — | |
| SCHEMBL8705872 | 0.73 | DRD2 (0.73) | DRD4DRD2SIGMAR1 | |
| SCHEMBL4581749 | 0.73 | CCNC (0.39) | — | |
| SCHEMBL4578993 | 0.72 | CCNC (0.54) | — | |
| SCHEMBL4580286 | 0.72 | PRKAA2 (0.58) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | PRKAA2 4491/4885PRKAB2 4072/4885PRKAG1 4025/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | PRKAA2 4491/4885PRKAB2 4072/4885PRKAG1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.